Conduit Pharmaceuticals Expands Stake Using Equity-Funded Acquisition Strategy

Conduit Pharmaceuticals ( (CDT) ) has shared an announcement.

On February 19, 2026, CDT Equity Inc. agreed to acquire 20% of Cayman Islands-based Sarborg Limited by issuing 598,006 common shares and pre-funded warrants for up to 109,978,918 additional shares, plus a deferred $8 million cash payment contingent on future fundraising. The deal involves related parties on the board, requires shareholder approval under Nasdaq rules for warrant exercise, and includes plans to register the resale of the new equity, signaling significant potential dilution for existing investors.

The company also extended two key consulting agreements in late February 2026, paying NJS Foresight Bio-Advisory and Thesprogen in additional common stock to prolong business development and scientific advisory support through late 2027. In a separate move, it issued more shares to Maxim Partners LLC for investment banking services, underscoring a strategy of using unregistered equity issuances to fund acquisitions, advisory work, and capital markets engagement while conserving cash.

More about Conduit Pharmaceuticals

Conduit Pharmaceuticals, through its subsidiary CDT Equity Inc., operates in the biopharmaceutical sector, focusing on developing and out-licensing a portfolio of drug assets. The company leverages external advisory and scientific consultants to optimize pre-clinical development, including work on AZD1656 in indications such as COPD and fibrosis, and to identify licensing partners for its pipeline.

Average Trading Volume: 584,591

Technical Sentiment Signal: Sell

Current Market Cap: $2.4M

For detailed information about CDT stock, go to TipRanks’ Stock Analysis page.